-
Carboplatin and Metabolic State in NSCLC Assays
2026-08-25
Carboplatin is a platinum-based DNA synthesis inhibitor whose activity can be interpreted more precisely when DNA damage is studied alongside tumor metabolism. This guide connects carboplatin assay design with CIP2A–PKM2 oxidative metabolism findings in NSCLC to improve model selection, endpoint analysis, and translational relevance.
-
Influenza Hemagglutinin (HA) Peptide Guide
2026-08-25
Influenza Hemagglutinin (HA) Peptide is a synthetic YPYDVPDYA epitope reagent for detecting, immunoprecipitating, and competitively eluting HA-tagged proteins. The A6004 product combines greater than 98% analytical purity with reported solubility in DMSO, ethanol, and water, supporting controlled protein-interaction workflows.
-
TBST (Tris-Buffered Saline and Tween 20) Guide
2026-08-24
TBST helps reduce nonspecific binding and background in antibody-based workflows by combining Tris-buffered saline with Tween 20 for blocking, antibody dilution, and washing. It is suited to Western blotting, immunofluorescence, immunohistochemistry, and immunocytochemistry, but requires validation in assays sensitive to non-ionic detergents.
-
HyperScript™ RT SuperMix for qPCR in PDAC
2026-08-24
HyperScript™ RT SuperMix for qPCR supports reproducible cDNA synthesis for gene expression analysis in pancreatic cancer cell-fate studies. This article explains how reverse transcription design can clarify adipogenic transdifferentiation, EMT suppression, and RNA template low concentration detection.
-
Bradykinin B2 Receptors and Ileal Peristalsis
2026-08-23
Chan and Rudd showed that bradykinin suppresses the peristaltic reflex in the guinea pig isolated ileum through B2, rather than B1, kinin receptors. Their combination of agonist profiling, selective antagonism, and pressure-threshold measurements provides a useful pharmacological framework for separating receptor-mediated inhibition from broader changes in intestinal contractility.
-
Oseltamivir acid: Translational Research Workflows
2026-08-22
Oseltamivir acid combines a direct neuraminidase mechanism with practical applications in influenza antiviral research, resistance profiling, and oncology models. This workflow-focused guide covers assay setup, comparative exposure studies, combination testing, and troubleshooting for reproducible results.
-
Angiotensin 1/2 (5-7): From RAS to Translation
2026-08-22
A translational framework for using Angiotensin 1/2 (5-7) to connect renin-angiotensin system biology, vascular assays, and emerging SARS-CoV-2 receptor-binding research without overstating the evidence.
-
IDH2 Reprogramming Drives CRC Through HIF-1α
2026-08-21
The reference study identifies mitochondrial IDH2 as a metabolic driver of colorectal cancer progression, linking reductive citrate-cycle activity to α-ketoglutarate availability, HIF-1α stabilization, glycolysis, and tumor growth. Its perturbation strategy suggests that metabolic interventions should be evaluated through coordinated measurements of mitochondrial energy production and hypoxia signaling rather than through glycolytic readouts alone.
-
Oseltamivir Acid: From Target to Assay
2026-08-20
Oseltamivir acid is an influenza neuraminidase inhibitor whose value depends on connecting enzyme inhibition with virion-release and resistance assays. This guide adds a translational assay-design framework informed by humanized-mouse pharmacokinetic research, while distinguishing established evidence from practical recommendations.
-
Clozapine N-oxide (CNO) in Chemogenetic Research
2026-08-20
Clozapine N-oxide (CNO) is a clozapine metabolite used to activate engineered muscarinic DREADDs for controlled neuronal activity modulation. Its research value depends on receptor validation, ligand-only controls, and careful solution handling.
-
Cathepsin B inhibitor CA-074: Practical Guide
2026-08-19
CA-074 provides a selective tool for testing whether cathepsin B activity contributes to proteolysis, cancer metastasis, neurotoxic responses, or immune response modulation. It is appropriate for controlled biochemical and exploratory cellular studies, but dossier-reported selectivity and HUVEC tolerability should not be treated as proof of activity, safety, or efficacy in every model.
-
Lenalidomide (CC-5013) Myeloma Research Workflows
2026-08-19
Build reproducible Lenalidomide assays around immune restoration, angiogenesis phenotyping, and multiple myeloma combination research. This workflow also translates new DOT1L–innate immune findings into practical controls, timing studies, and troubleshooting decisions.
-
A. dahurica Pyranocoumarins Target NF-κB and MAPK
2026-08-18
A 2026 Journal of Ethnopharmacology study used activity-guided isolation to identify 35 compounds from Angelica dahurica, including a newly identified furocoumarin, and found that pyranocoumarins 2 and 3 most strongly reduced LPS-induced inflammatory responses. The work connects reduced nitric oxide and cytokine production with coordinated suppression of NF-κB and MAPK signaling, while also defining the limits of evidence from a macrophage-based in vitro model.
-
Sulfamonomethoxine Workflows for Aquaculture Research
2026-08-18
Sulfamonomethoxine supports mechanism-led studies spanning veterinary microbiology, aquaculture screening, and environmental fate analysis. This guide turns its folate-pathway activity and limited protozoan potency into practical assay, formulation, and troubleshooting decisions.
-
Clarithromycin in CYP3A Interaction Assays
2026-08-17
Build more interpretable CYP3A inhibition experiments with Clarithromycin by controlling solvent, preincubation, exposure, and orthogonal readouts. The workflow also uses dabigatran etexilate’s CYP450-independent disposition as a carefully qualified negative-control concept for separating CYP3A effects from broader assay artifacts.